Development of prostrate cancer vaccine using PAP as target antigen

Javad, J.M.S., 2014. Development of prostrate cancer vaccine using PAP as target antigen. PhD, Nottingham Trent University.

Preview

Text 218440_Javad.pdf Download (3MB) | Preview

Abstract

Treatment options for patients with advanced prostate cancer (PC) still remain limited and rarely curative. The prostatic acid phosphatase (PAP) is prostate specific protein over-expressed in more than 90% of prostate tumours. Although an FDA-approved vaccine for the treatment of advanced prostate disease, PROVENGE® (sipuleucel-T), has been shown to prolong survival, the precise sequence of the PAP protein responsible for the outcome remains unknown. As the PAP antigen is one of the very few prostate-specific antigens for which there is a rodent equivalent with high homology, pre-clinical studies using PAP have the potential to be directly relevant to the clinical setting. The current study identified HLA-A2 and HLA-DR1 PAP-derived peptides using the transgenic HHDII/DR1 and C57Bl/6 mice. The PAP-114-128 (15-mer) peptide was shown to elicit CD4+ and CD8+ T-cell-specific responses in C57Bl/6 mice. Furthermore, when immunised in a DNA vector format (ImmunoBody), PAP-114-128 was able to prevent and reduce the growth of TRAMP C1 prostate cancer cell-derived tumours in both prophylactic and therapeutic settings.

Item Type:	Thesis
Creators:	Javad, J.M.S.
Date:	2014
Rights:	This work is the intellectual property of the author. You may copy up to 5% of this work for private study, or personal, non-commercial research. Any re-use of the information contained within this document should be fully referenced, quoting the author, title, university, degree level and pagination. Queries or requests for any other use, or if a more substantial copy is required, should be directed in the owner(s) of the Intellectual Property Rights.
Divisions:	Schools > School of Science and Technology
Record created by:	EPrints Services
Date Added:	09 Oct 2015 09:33
Last Modified:	05 Dec 2017 16:30
URI:	https://irep.ntu.ac.uk/id/eprint/59

Actions (login required)

Edit View

Views

Downloads